Maplelane Capital’s Merck MRK Stock Holding History

Maplelane Capital’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-628,800	Closed	-$49.8M	–	175
2020 Q3	$49.8M	Buy	+628,800	New	+$49.3M	0.91%	30

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Maplelane Capital's MRK Position: Q4 2020 in Review

Maplelane Capital sold out of Merck (MRK) in Q4 2020, closing a stake of 1 share.

Maplelane Capital first reported a position in MRK in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 2,708 funds tracked by Wall St. Rank hold MRK as of Q4 2020.

Maplelane Capital reported no remaining Merck position as of Q4 2020 after selling out during the quarter.
Maplelane Capital sold 1 Merck share in Q4 2020.
Maplelane Capital first reported a position in Merck in Q3 2020 and held it in 1 quarter.
Maplelane Capital's Merck position peaked at $0 in Q3 2020.
2,708 funds tracked by Wall St. Rank held Merck as of Q4 2020.

Based on Maplelane Capital's 13F filing for Q4 2020, filed 16 Feb 2021.